A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Vista sencilla de ítem
dc.creatorShi, Rui
dc.creatorShan, Chao
dc.creatorDuan, Xiaomin
dc.creatorChen, Zhihai
dc.creatorLiu, Peipei
dc.creatorSong, Jinwen
dc.creatorSong, Tao
dc.creatorBi, Xiaoshan
dc.creatorHan, Chao
dc.creatorWu, Lianao
dc.creatorGao, Ge
dc.creatorHu, Xue
dc.creatorZhang, Yanan
dc.creatorTong, Zhou
dc.creatorHuang, Weijin
dc.creatorLiu, William Jun
dc.creatorWu, Guizhen
dc.creatorZhang, Bo
dc.creatorWang, Lan
dc.creatorQi, Jianxun
dc.creatorFeng, Hui
dc.creatorWang, Fu sheng
dc.creatorWang, Qihui
dc.creatorGao, George Fu
dc.creatorYuan, Zhiming
dc.creatorYan, Jinghua
dc.date.accessioned2020-07-17T23:49:36Z
dc.date.available2020-07-17T23:49:36Z
dc.date.created2020-05-26
dc.description.abstractenglishAn outbreak of coronavirus disease 2019 (COVID-19)1,2,3, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4, has spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. Here we report the isolation of two specific human monoclonal antibodies (termed CA1 and CB6) from a patient convalescing from COVID-19. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro. In addition, CB6 inhibited infection with SARS-CoV-2 in rhesus monkeys in both prophylactic and treatment settings. We also performed structural studies, which revealed that CB6 recognizes an epitope that overlaps with angiotensin-converting enzyme 2 (ACE2)-binding sites in the SARS-CoV-2 receptor-binding domain, and thereby interferes with virus–receptor interactions by both steric hindrance and direct competition for interface residues. Our results suggest that CB6 deserves further study as a candidate for translation to the clinic.spa
dc.format.extent26 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41586-020-2381-yspa
dc.identifier.issn1476-4687spa
dc.identifier.otherhttps://www.nature.com/articles/s41586-020-2381-yspa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10823
dc.publisherScience Directeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectAnticuerpos neutralizantes humanosspa
dc.subject.keywordHuman neutralizing antibodyspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleA human neutralizing antibody targets the receptor-binding site of SARS-CoV-2spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
s41586-020-2381-y_reference.pdf
Tamaño:
11.34 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS